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Abstract The potential anticancer agent fostriecin (FOS) is a
potent inhibitor of the protein Ser/Thr phosphatases PP2A and
PP4 and a weaker inhibitor of PP1. Random mutagenesis and
automated screening in yeast identified residues in human
PP2AcK important for inhibitory FOS binding. A C269S
substitution in the predicted L12^L13 loop decreased the FOS
sensitivity of intact cells and increased the IC50 of PP2AcK by
10-fold in vitro. Changing PP2AcK Cys-269 to phenylalanine,
the equivalent residue in PP1, and the Y267G and G270D
substitutions caused a similar effect. The results provide
information relevant to the design of novel protein Ser/Thr
phosphatase inhibitory drugs. ß 2001 Published by Elsevier
Science B.V. on behalf of the Federation of European Biochem-
ical Societies.
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1. Introduction
Fostriecin (FOS; NSC339638) is a structurally novel anti-
tumor antibiotic [1,2]. Preclinical studies have revealed potent
activity against murine leukemias dependent upon the unsat-
urated lactone and phosphate ester moieties [3]. Moreover,
FOS displays antineoplastic activity against human tumor
cells in vitro [4] and it has been evaluated as an anticancer
drug in human patients [5]. The antitumor activity of FOS is
mediated apparently by interference with reversible protein
phosphorylation [6]. It inhibits the activity of protein Ser/
Thr phosphatases (PPAs), an important family of enzymes
with diverse roles in the control of signal transduction, growth
and cell division [7]. Thus, FOS inhibits PP2A (inhibitory
concentration (IC)50V1 nM) and PP4 (IC50V3 nM) potently,
and the related PP1 enzyme weakly (IC50V131 WM) [8^10]
but does not inhibit PP2B [8].
The crystal structure of PP1 [11,12] and molecular modeling
[13,14] have predicted residues important for the interaction
of PP1 and PP2A with several inhibitors. Mutagenesis of PP1
highlighted the C-terminal L12^L13 loop as a region impor-
tant for inhibitor binding [15,16]. This £exible portion of the
molecule protrudes over the active site and may impede access
to substrates when inhibitors are bound [11,12]. It encom-
passes an amino acid sequence (SAPNYC) that is highly con-
served in PP1 and PP2Ac, and downstream residues that di-
verge between PP1 and PP2Ac and contribute to the
di¡erential sensitivity of these enzymes to inhibitors
[10,17,18].
The importance of PP1 and PP2Ac C-terminal residues for
inhibitor binding was further de¢ned by experiments employ-
ing the PP1 catalytic core enzyme and a chimeric protein,
CRHM2, consisting of N-terminal PP1 residues and C-termi-
nal residues from PP2Ac [8,10]. These studies indicated that
residues C-terminal to the PP1 catalytic core are important for
the binding of several protein and toxin inhibitors, including
okadaic acid (OA) and microcystin-LR, while PP1 core resi-
dues alone mediate the binding of FOS. We extend these ob-
servations to reveal that, in the context of the full length
PP2AcK molecule, Cys-269 in the predicted L12^L13 loop
participates in an interaction with FOS that, while absent
from PP1, promotes inhibition of PP2A.
2. Materials and methods
2.1. Media, drugs, strains and plasmids
Rich (YPD and YMI), synthetic (C) and 5-£uoroorotic acid (5-
FOA) media were described [19]. OA (Calbiochem) and FOS (DTP-
NCI) were suspended to 20 mM in dimethyl sulfoxide (DMSO) and
stored at 4‡C (OA) or 340‡C (FOS). Prior to use FOS was diluted
into bu¡er containing ascorbic acid at 0.1 mM to protect against
oxidation. DEY779-1 (a erg6v1: :TRP1 pdr1v1: :LEU2 pdr3v1: :hisG
bub3v1 ura3, A364a) is a Ura3 recombinant of strain SPY507791.
Strains DEY3 [20] and DEY1-CK [21] are deleted for the chromoso-
mal genes PPH21, PPH22 and PPH3 encoding yeast PP2Ac and
Pph3p. Viability of DEY3 is dependent on plasmid YCpDE8
(URA3 PPH22) encoding yeast PP2Ac [20]. Strain DEY1-CK lacks
yeast PP2Ac and is dependent on human PP2AcK expressed at a low
level from the PGK1 promoter of YEpDE-PGK-CK (TRP1) [21].
YEpDE2e is PPH22HA encoding hemagglutinin (HA)-tagged yeast
PP2Ac [22] in YEp352. Plasmid YCpDE-ADHU-CHA is the HA-
PP2AcK cDNA (BamHI/EcoRI fragment) from YCpDE-PGK-CHA
[21] expressed from the ADH1 promoter. Cell number was determined
using a hemocytometer.
2.2. Drug toxicity assays with intact yeast cells
Toxicity assays were performed as per Simon et al. [23]. FOS was 3-
fold serially diluted in 5% DMSO and aliquots (15 Wl) were dispensed
in duplicate to a Nunc U96 PP 0.5 ml 96-well plate. DMSO (15 Wl)
was dispensed in duplicate to control wells. Cells grown in selective
(C-ura or C-trp) medium were diluted to 5U104 cells per ml and
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dispensed (135 Wl) into each well. Cultures were incubated at 30‡C for
18^24 h until the A660 of control cultures was 0.35^0.45 (Bio-Tek
Instruments EL340 microplate reader). Relative growth was (A660
with drug/A660 without drug).
2.3. Mutagenesis of human PP2AcK and selection for functional mutant
forms
An 870 bp fragment from YEpDE-PGK-CK, encoding 653 bp of
the PP2AcK 3P open reading frame (ORF) and 217 bp of vector, was
ampli¢ed by mutagenic PCR [21]. A 970 bp cDNA encoding human
PP2Ac-225-1 [21] was inserted into vector pYPGE2(TRP1) and
cleaved with A£II/BstEII within the ORF. To produce a library of
PP2AcK mutant clones the gapped plasmid and mutant PCR products
were introduced into strain DEY3 [20]. Transformants (V55 000)
were selected on C-trp medium then replicated to 5-FOA to select
for Ura3 recombinants (V10 000) lacking yeast PP2Ac and express-
ing a functional PP2AcK. Site directed mutagenesis of PP2AcK in
plasmid YEpDE-PGK-CHA [21] was performed using QuickChange
(Stratagene).
2.4. Identi¢cation of functional PP2AcK mutant forms conferring FOS
resistance
Na|«ve strains (1216) were patched onto C agar containing FOS (100
WM), incubated at 30‡C for 2 days and scored for growth relative to
strain DEY1-CK. Additional strains (184) were screened by auto-
mated, high-throughput toxicity assays in which strains were inocu-
lated (30 Wl) initially into duplicate wells of a 96-well plate containing
liquid C (270 Wl). Saturated cultures were serially diluted to 5U104
cells per ml using a MATRIX PlateMATE 96/384 Automated Pippet-
tor robot (OPAL/JENA software) and distributed (135 Wl) to two 96-
well plates with FOS (15 Wl) at 100 WM or 400 WM, or DMSO (15 Wl)
at 5% in the wells. Duplicate control cultures of DEY1-CK were in-
cluded on each plate. Cells were deemed drug resistant if relative
growth was 1.8-fold and 1.4-fold higher than that of DEY1-CK in
the presence of 10 WM and 40 WM drug, respectively. In an alternative
enrichment approach, colonies functionally expressing PP2AcK were
pooled from 5-FOA agar into liquid C. An aliquot (3U106 cells) was
inoculated into C (3 ml) containing FOS (40 WM) and ascorbic acid
(0.1 mM). After 2 days at 30‡C a fresh sample of FOS was added to
40 WM. After a further 3 days independent colonies (138) were iso-
lated on YPD and screened for FOS resistance by automated toxicity
assay.
2.5. Partial puri¢cation of PP2AcK proteins from yeast, and Western
blot analysis
PP2AcK proteins were tagged with the HA epitope [21] and indu-
cibly expressed from vector pYES2 in strain INVSC1 (Invitrogen)
[21]. HA-tagged proteins were immunoprecipitated from cell extracts
(V1 mg) and eluted from beads with HA peptide (Boehringer Mann-
heim) as described [21,24] except the monoclonal HA.11 (0.4 mg;
Covance) was bound to Gammabind Plus Sepharose (1 ml; Amer-
sham Pharmacia Biotech). Tagged proteins were analyzed by Western
blotting as described [21] using HA.11 as probe.
2.6. Protein phosphatase activity measurements
Partially puri¢ed PP2AcK was eluted from beads and assayed for
activity as using malachite green to measure phosphate release from a
peptide substrate (RRA(pT)VA) (Promega V2460) as described [21].
Assays (50 Wl) were performed in duplicate in a 96-well plate (Costar
3690; Corning). Puri¢ed rabbit muscle PP2Ac (V6311) was obtained
from Promega.
3. Results
3.1. Fostriecin targets PP2Ac in yeast cells
Fostriecin (FOS) blocks the proliferation of mammalian
cells and inhibits the activity of PP2Ac [6,8,25] and PP4 [9]
potently. Recently we found that FOS inhibits yeast cell
growth, and that the inhibition is exacerbated in the absence
of the BUB3 gene1. In an attempt to understand the biological
e¡ects of FOS we tested whether PP2Ac is a target in yeast
cells. In a toxicity assay [23] FOS inhibited the growth of
bub3v cells potently (IC506 1.0 WM) but its toxic e¡ect was
reduced (IC50V4 WM) by increased dosage of the yeast
PP2Ac gene (Fig. 1A). A similar e¡ect (V2.4-fold increase
in IC50) was observed using BUB3 cells (not shown). More-
over, drug resistance was conferred by expression of human
PP2AcK from the strong ADH1 promoter in cells lacking the
endogenous yeast enzyme (Fig. 1B). These results indicate that
PP2Ac is a target of FOS in yeast.
3.2. Identi¢cation and functional analysis of FOS-resistant
forms of PP2AcK in yeast
To identify amino acids important for the inhibition of
PP2Ac by FOS, the human PP2AK cDNA was subjected to
random mutagenesis and PP2AcK mutant forms that substi-
tuted for yeast PP2Ac were tested for FOS resistance (Section
2). Thus, 1400 strains functionally expressing a PP2AcK pro-
tein were patched onto agar containing FOS at 100 WM, or
inoculated into liquid medium and tested for FOS resistance
at 10 WM and 40 WM by automated screening. This yielded
one PP2AcK mutant cDNA (N1) that conferred drug resis-
tance following plasmid rescue and reintroduction into the
host strain (inset to Fig. 2). By an alternative strategy, yeast
strains (V5000) functionally expressing PP2AcK were pooled
and an aliquot was inoculated into medium containing FOS
at 40 WM to enrich for drug-resistant cells. After 5 days, in-
dependent colonies were tested for FOS resistance at 10 WM
and 40 WM by automated screening. By this approach, three
Fig. 1. Increased PP2Ac gene dosage suppresses FOS inhibition of
yeast growth. A: Elevated PPH22 dosage confers FOS resistance.
Toxicity was assayed in bub3v cells (strain DEY779-1) containing
plasmid YEpDE2e (2W PPH22, encoding yeast PP2Ac; open circles)
or empty vector (¢lled circles). B: Expression of human PP2AcK
from the yeast ADH1 promoter confers FOS resistance. A plasmid
expressing PP2AcK from the strong ADH1 promoter (PP2AcK
high), or empty vector (PP2AcK low) was introduced into strain
DEY1-CK. Cells were grown to saturation in C-ura medium,
10-fold serially diluted, spotted onto YPD agar containing FOS
(100 WM) or drug vehicle (DMSO) and incubated at 30‡C for 48 h.
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PP2AcK cDNAs (E1, E2 and E3) were isolated that conferred
drug resistance reproducibly following plasmid rescue (Fig. 2).
Analysis of cDNAs N1 and E1^E3 revealed a single trans-
version (t805Ca) in each encoding the PP2AcK C269S sub-
stitution. Cells functionally expressing PP2AcK C269S exhib-
ited a rate of proliferation (population doubling time (td) 102
min at 30‡C in YMI) similar to that of cells expressing wild-
type PP2AcK (td 105 min; strain DEY1CK) indicating that the
mutant protein is largely functional. Remarkably, a substitu-
tion at the same position (C269G) was identi¢ed during a
screen for PP2AcK mutations conferring OA resistance in
Chinese hamster ovary (CHO)-K1 cells [25]. Furthermore
Cys-269 lies within a C-terminal region of PP2Ac, the pre-
dicted L12^L13 loop, that is partly conserved in PP1 [11,12].
This region encompasses a conserved SAPNYC motif and
residues immediately downstream (GEFD in PP1 and
YRCG in PP2Ac) which contribute to the di¡erential sensi-
tivity of PP1 and PP2Ac to inhibitors [8,10,15^18]. Because
FOS is highly speci¢c (V40 000-fold) for the inhibition of
PP2Ac relative to PP1 [8], each residue in the PP2AcK
YRCG motif (including Cys-269) was changed individually
to the equivalent residue in PP1. In addition, phenylalanine
was substituted for Tyr-265 in the PP2AcK SAPNYC motif
because the equivalent mutation in PP1 confers resistance to
OA, calyculin A and tautomycin [15]. The mutant proteins
were tested in yeast, for function in vivo and FOS resistance.
The PP2AcK Y265F and R268E mutant proteins were non-
functional suggesting that they are improperly folded in vivo,
and they were not studied further. In contrast, PP2AcK
C269F supported a wild-type rate of cell proliferation (td
102 min) and conferred resistance to FOS (V4-fold increase
in IC50 ; Fig. 3A). Similarly, the Y267G and G270D forms
supported wild-type proliferation (td 100 and 92 min, respec-
tively) and caused decreased sensitivity to FOS (1.4-fold in-
crease in IC50) (Fig. 3A) that was observed clearly in cells
grown on agar (Fig. 3B). These data support the conclusion
that Cys-269 and adjacent residues are important for inhibi-
tion of PP2AcK by FOS.
3.3. The PP2AcK C269S substitution confers FOS resistance in
vitro
To investigate the role of Cys-269 in drug inhibition of
PP2Ac activity, the PP2AcK wild-type and C269S mutant
proteins were partially puri¢ed from yeast. A similar amount
(Fig. 4A) and total activity (see legend to Fig. 4B and C) of
enzyme was recovered from yeast expressing the wild-type or
mutant form, and each enzyme displayed a similar rate of
Fig. 2. FOS resistance of yeast cells expressing PP2AcK mutant
cDNAs. Cells from a saturated culture and expressing a wild-type
(¢lled squares) or mutant (E1, open squares; E2, open circles; E3,
¢lled circles) form of PP2AcK were assayed for growth in liquid me-
dium containing FOS. Numbers are mean values ( þ S.D.) from
three independent experiments. The inset shows a similar experiment
with cells expressing wild-type PP2AcK (¢lled squares) or a mutant
form encoded by cDNA N1 (open squares).
Fig. 3. FOS resistance of cells expressing a PP2AcK form mutated
in the predicted L12^L13 loop. A: Toxicity assay of FOS sensitivity.
Cells functionally expressing a wild-type (crosses) or mutant
(C269F, ¢lled squares; C269S, ¢lled circles; G270D, open circles;
Y267G, open squares) PP2AcK were assayed for FOS sensitivity.
Numbers are mean values ( þ S.D.) from three independent experi-
ments. B: Growth on YPD agar. Cells containing a cDNA encod-
ing a wild-type (PP2AcK) or mutant (Y267G, G270D, C269F)
PP2AcK were tested for growth in the presence (FOS, 150 WM or
200 WM) or absence (DMSO) of drug as in Fig. 2. Similar results
were obtained in three experiments.
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phosphopeptide substrate hydrolysis in vitro (not shown).
Above a concentration of 0.5 nM, OA inhibited wild-type
PP2AcK activity (apparent IC50V3 nM) in a dose dependent
manner (Fig. 4B). Similarly, FOS inhibited PP2AcK activity
(apparent IC50V500 nM) in a dose dependent manner (Fig.
4C), but less potently than OA as observed by Walsh et al. [8].
The high apparent IC50 of wild-type PP2AcK for OA and
FOS in these experiments is likely due to a high concentration
of enzyme present in the assay, causing drug titration as de-
scribed previously [8]. The fold di¡erence between the appar-
ent and reported IC50 of wild-type PP2AcK for OA (30-fold)
and FOS (s 100-fold) was di¡erent. The reason for this is
unclear but the e¡ect is inherent to our assay, as under the
same conditions the IC50 of puri¢ed rabbit muscle PP2Ac for
OA and FOS was similar to that of the PP2AcK enzyme
partially puri¢ed from yeast (not shown). Notably, the
C269S substitution caused a decrease in the sensitivity of
PP2AcK to OA (V3^4-fold increase in IC50) (Fig. 4B) similar
to that reported for the C269G substitution [25]. Moreover,
consistent with the results obtained with intact cells, the ac-
tivity of the PP2AcK C269S mutant enzyme was strikingly
resistant to inhibition by FOS (apparent IC50s 5.0 WM)
(Fig. 4B) supporting the conclusion that Cys-269 is important
for inhibition of PP2AcK by this drug.
4. Discussion
To identify novel anticancer agents we have been screening
for compounds that inhibit yeast cell growth speci¢cally in the
context of cancer-like mutations [23]. FOS was identi¢ed in
this screen due to di¡erential inhibition of bub3v mutant cells
defective for the kinetochore/spindle checkpoint1. Towards an
understanding of the inhibitory e¡ect of FOS we have inves-
tigated whether PP2Ac is a cellular target in yeast. Consistent
with this, we demonstrate that increased dosage of PP2Ac
enhances the tolerance of yeast cells to FOS, apparently via
drug titration [26], and we identify mutations in PP2AcK that
confer FOS resistance.
The PP2AcK C269S substitution, located within a region
equivalent to the PP1 L12^L13 loop [11,12], increased the
FOS resistance of intact cells and the IC50 of the partially
puri¢ed enzyme. Similar to C269G [25], C269S increased
the IC50 of PP2AcK for OA by 4-fold indicating that Cys-
269 is important for FOS and OA binding by PP2AcK.
Because it is absent from PP1, Cys-269 must contribute to
the 40 000-fold greater sensitivity of PP2Ac to FOS [8]. Ac-
cordingly, changing Cys-269 to phenylalanine, the corre-
sponding residue in PP1, increased the FOS resistance of in-
tact cells.
Our results were unexpected because FOS inhibition of PP1
requires residues in the catalytic core, but not in the L12^L13
loop [10]. Thus a PP1 core enzyme, lacking residues down-
stream of alanine in the SAPNYC motif, and a chimeric en-
zyme CRHM2, consisting of PP2Ac C-terminal residues fused
to PP1 at the SAPNYC motif, exhibit FOS sensitivity char-
acteristic of full length PP1 [8,10]. However, within the con-
text of PP2AcK, Cys-269 contributes to the potent inhibition
of activity by FOS because C269S increased the IC50 by at
least 10-fold. Nevertheless, PP2AcK C269S was inhibited by
40% in the presence of 5 WM FOS, contrasting with PP1 and
CHRM2 which are inhibited with an IC50 of s 100 WM [8,10].
Indeed our measurements underestimate the inhibition of
PP2AcK C269S because the apparent IC50 of wild-type
PP2AcK for FOS in our assay was s 100-fold higher than
that calculated for the puri¢ed enzyme diluted to a titration
endpoint [8]. The intermediate sensitivity of PP2AcK C269S to
FOS, together with results obtained from structural analysis
Fig. 4. Analysis of PP2AcK activity in vitro. A: Western blot analy-
sis of partially puri¢ed PP2AcK proteins. A plasmid encoding the
HA-tagged wild-type or C269S form of PP2AcK (36 kDa), or the
empty vector, was introduced into strain INVSC1. Yeast cell ex-
tracts (30 Wg; extract), and immune complexes (IP) released from
beads by boiling, were resolved by sodium dodecyl sulfate^polyac-
rylamide gel electrophoresis (SDS^PAGE) (10%) prior to Western
blot analysis. Lanes 1 and 4, wild-type PP2AcK ; lanes 2 and 5,
PP2AcK C269S; lanes 3 and 6, no HA-tagged protein (empty vec-
tor). Results are representatives of two independent preparations.
B/C: Protein phosphatase assays in vitro. The PP2AcK wild-type
and C269S mutant enzymes were partially puri¢ed from yeast and
assayed for activity in the presence of OA (B) or FOS (C). Data
are expressed as % of control activity in the absence of drug.
B: Numbers are mean values from two independent experiments.
Control activity was 39.2 þ 3.4 WU (wild-type; n = 2) and 30.1 þ 8.9
WU (C269S; n = 2). C: Mean values ( þ S.D.) from three independent
experiments. Control activity was 41.1 þ 4.9 WU, wild-type (n = 3)
and 40.5 þ 1.4 WU, C269S (n = 3). Control activities were corrected
for background activity (A, 7.5 þ 1.3 WU, n = 2 and B, 6.9 þ 0.6 WU,
n = 3) present in eluates lacking HA-tagged protein.
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and mutagenesis of PP1 [8,10,11,16] predict that in addition to
Cys-269, residues within the PP2AcK catalytic core are impor-
tant for inhibitory FOS binding.
Amino acid sequence alignment (Fig. 5) reveals that PP2Ac
and PP4 share residues that are absent from PP1 and PP2B
and therefore are candidates for mediators of high-a⁄nity
FOS binding. We propose that Cys-269 orients FOS optimally
in relation to an active site residue(s) that may be unique to
PP2Ac and PP4 and which mediates high-a⁄nity FOS bind-
ing. The screen employed in this study may not have identi¢ed
core amino acids involved in FOS binding because it included
a selection for PP2AcK function in vivo, and mutation of
active site residues can impair catalytic function. However,
substituting an alternative residue for PP2AcK Cys-269 may
weaken FOS binding by disrupting the structural relationship
between the L12^L13 loop and the active site. The increase
in FOS resistance caused by the Y267G and G270D substitu-
tions (V1.4-fold increase in the IC50 of intact cells) located
adjacent to Cys-269 is consistent with this. Interestingly, the
unsaturated lactone of FOS resembles the KL unsaturated
N-methyldehydroalanine (Mdha) residue in microcystin-LR,
the side chain of which forms a covalent linkage with Cys-
273 in the PP1 L12^L13 loop [11]. Thus FOS may bind
the equivalent Cys-266 residue in PP2AcK. However, the
covalent linkage between Mdha and PP1 Cys-273 is not
essential for enzyme inhibition [27,28] and our data do not
rule out a direct interaction between PP2AcK Cys-269 and
FOS.
Fostriecin confers an antitumor e¡ect at concentrations
that may inhibit the activity of both PP2AcK and PP1 [4].
An understanding of the molecular interactions occurring be-
tween protein Ser/Thr phosphatase inhibitors and their targets
may help in the design of novel drugs with increased e⁄cacy
and reduced general toxicity.
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